Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms

Nellowe Candelario\textsuperscript{a,b}, Christopher Geiger\textsuperscript{a,b} and Thomas Flaig\textsuperscript{a,b,∗}

\textsuperscript{a}University of Colorado Cancer Center, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA
\textsuperscript{b}Division of Medical Oncology, School of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA

Received 1 July 2021
Accepted 8 October 2021
Pre-press 26 October 2021
Published 3 December 2021

Abstract. Sarcomatoid renal cell carcinoma (sRCC) is an aggressive form of kidney cancer that is associated with poor prognosis. It can arise from any histologic type of renal cell carcinoma. The majority of cases will present with advanced or metastatic disease requiring systemic therapy. Nephrectomy is the treatment of choice in locally resectable disease. The therapeutic options for sRCC have evolved in the past decade. Cytotoxic chemotherapy and monotherapy with targeted therapy (VEGF and mTOR) have historically shown poor response rates and survival in the treatment of metastatic sRCC. The use of checkpoint inhibitors and their combination with targeted therapy against VEGF has changed the landscape and outcomes for renal cell carcinoma. Given the rarity of sRCC most of the data on treatment is from small cohorts or extrapolation from larger clinical trials. The benefit from the combination of checkpoint inhibitors and targeted therapy to VEGF has shown promise in the sRCC population in post hoc analysis of large clinical trials. Future research focusing on further characterizing the unique biologic and clinical features of sRCC is critical in advancing the knowledge and developing effective therapy to improve clinical outcomes and survival.

INTRODUCTION

Kidney cancer is ranked as the 14th most common type of cancer worldwide. There are 76,080 estimated new cases of kidney and renal pelvis malignancies in the United States in 2021 representing 4% of all cancer cases. Approximately 13,780 people will die from kidney cancer in the United States in 2021 \cite{1, 2}. Renal cell carcinoma (RCC) is classified based on morphologic, molecular, and genetic features. The most common type is clear cell which accounts for 70–90% of cases. Other rare histologic types include the papillary and chromophobe types of renal cell carcinoma \cite{3–5}.

Renal cell carcinoma with sarcomatoid dedifferentiation (sRCC) is an aggressive form of kidney cancer that portends a poor prognosis \cite{5, 6}. Although it was historically classified as a distinct type of renal cell carcinoma, sRCC is now understood to be a dedifferentiation of renal carcinoma \cite{6}. Sarcomatoid transformation can occur in any morphologic type of renal cell carcinoma. It is unknown if the primary histologic type undergoing sarcomatoid transformation affects prognosis. One series found the incidence of sarcomatoid differentiation was 8% in clear cell renal carcinoma, 3% in papillary renal carcinoma, 9% in chromophobe renal carcinoma, 29% in collecting duct carcinoma, and 11% in unclassified renal cell carcinoma \cite{7}. Sarcomatoid renal cell carcinoma is characterized by a tumor composed of malignant spindle cells that have features of epithelial, stromal and myxoid components. The presence of sarcomatoid features in any type of renal cell carci-
noma is classified as a poorly differentiated or high grade (Grade 4) disease [8–10]. Sarcomatoid dedifferentiation in RCC is an independent predictor of mortality regardless of stage of disease; in a stage-by-stage analyses, sRCC patients have worse survival [11–13].

The treatment paradigm for renal cell carcinoma has evolved in the past 20 years particularly in the advanced and metastatic stages with the advent of immunotherapy (CTLA-4, PD-1 and PD-L1 inhibitors) and therapy targeting the vascular endothelial growth factor (VEGF) pathway. This review aims to provide a perspective on the biology and current treatment strategies in the management of sRCC which can have implications for research development identifying additional targets of therapy.

PATHOLOGIC FEATURES AND BIOLOGY

Sarcomatoid renal cell carcinoma is characterized by pleomorphic spindle cells that resemble sarcoma [14]. The sarcomatoid dedifferentiation includes a variable amount of fibrosarcoma like or pleomorphic undifferentiated like patterns. In uncommon circumstances, features of osteosarcoma, chondrosarcoma or rhabdomyosarcoma can be appreciated. The presence of necrosis is almost universal [6, 7]. The proportion of sarcomatoid features within the clinical entity of sRCC may vary; there is no consensus percentage of sarcomatoid component required to classify a renal cell carcinoma as having sarcomatoid dedifferentiation. A small proportion, approximately 3%, of renal cell carcinoma, has been described as pure sarcomatoid [15]. Tumors with pure sarcomatoid features are identified as unclassified renal cell carcinoma (uRCC) given they do not have the distinctive features to be categorized further based on morphology. This is in contrast to RCC with 100% sarcomatoid features in which the histologic subtype can be identified [4, 5].

Although the classification of renal cell carcinoma as having sarcomatoid dedifferentiation does not require a minimum amount of sarcomatoid component on pathologic examination, the percentage of sarcomatoid features is clinically relevant [7, 15]. It has been shown that with every 10% increase in the sarcomatoid component of the tumor, there is a 6% proportionate increase in mortality and that patients with tumors containing more than 30% sarcomatoid differentiation have a higher mortality [11]. While most sRCC patients present with advanced or metastatic disease, patients with early localized disease with more than 25% sarcomatoid features have higher mortality and recurrence rates [12, 13].

Histologically, immunohistochemistry markers associated with a renal origin of the tumor includes PAX2, CD10 and PAX8 are usually observed in sRCC and epithelial markers such as keratin, AE1/AE3, vimentin and epithelial membrane antigen (EMA) may also be positive. Carbonic anhydrase IX (CAIX), which is specific for clear cell renal cell carcinoma, can be appreciated in some cases of sRCC [6, 16, 17]. It is important to note that sarcomatoid transformation can lead to loss of renal cell carcinoma markers, particularly CAIX, CD10 and PAX8. Positive staining for CAIX is associated with poor prognosis in sRCC [18]. The key factor in establishing a diagnosis of sRCC is the morphologic sarcomatoid component within the tumor. Sarcomatoid renal cell carcinoma is conventionally classified as high grade or grade 4 [7, 15, 16, 19].

There are proposed mechanisms for the development of sarcomatoid dedifferentiation of renal cell carcinoma. It has been theorized that the two components of the tumor could come from two independent cells of origin or a single cell origin leading to both epithelial and sarcomatoid components (Fig. 1) [20, 21]. Genomic profiling to identify driver mutations in sRCC showed identical mutations in the sarcomatoid and epithelial component. TP53 (42.3%), VHL (34.6%), CDKN2A (26.9%), and NF2 (19.2%) were the most frequently altered genes [22]. This suggests that the origin of the sRCC possibly arises from a common progenitor with sRCC. Molecular characterization of renal cell carcinoma has shown that sRCC has lower PBRM1 and KDM5C expression, and these findings may be associated with increased angiogenesis. It is also notable that sarcomatoid dedifferentiated tumors have higher expression of PD-L1 and alteration in CDK2A/B [23]. A better understanding of the genomic drivers of sRCC may help to develop clinically actionable biomarkers in the future.

CLINICAL PRESENTATION

Sarcomatoid renal cell carcinoma is an aggressive tumor with a median survival of 9 months. In the non-metastatic setting, sRCC generally presents as a locally advanced tumor, with over 25% of those with localized disease presenting with a T4 lesion (tumor extending beyond the Gerota’s fascia) and about one third with lymph node involvement [24,
Fig. 1. Tumor Biology of Sarcomatoid Renal Cell Carcinoma: There are several pathways involved in the pathogenesis of sRCC. These include MAPK, TGF, TNF beta, PI3K/AK and WNT pathways. Signals from these pathways lead to amplification of Snail, Zeb and Twist transcription factors. One of the central events in defining sRCC is an Epithelial Mesenchymal Transition (EMT). This happens due to a gain of mesenchymal component of the tumor characterized by upregulation of N-cadherin and loss of epithelial component from down regulation of E-cadherin. E-cadherin is a vital component of cell-to-cell adhesion to form tight junctions and its loss increases the propensity to metastasize, which is a key characteristic of the aggressive biology of sarcomatoid dedifferentiation of renal cell carcinoma [20].

Unfortunately, the majority of sRCC cancers are metastatic on presentation. The most common distant metastatic sites include lungs (67%), bone (40%), liver (21%), and brain (15%) [26, 27]. The pattern of metastasis has prognostic implications in RCC including patients with sRCC. Thyroid, adrenal, bowel, lung, and pancreatic metastases appear to have a better prognosis compared to brain, bone and liver metastases [28, 29].

Presenting signs and symptoms of sRCC are non-specific. The majority of patients will have abdominal or flank pain with or without hematuria. Patients with pulmonary metastasis can present with shortness of breath and cough. Constitutional symptoms are also seen, including fatigue, weight loss, fever, and night sweats [20, 24, 26].

**TREATMENT**

**Surgical management**

Nephrectomy offers a potential cure for localized or early-stage sRCC. However, localized or early stage sRCC patients have poor outcomes even with optimal surgical management. A single center study of localized sRCC patients after nephrectomy found that the median time to recurrence of disease was 26 months [30]. The optimal surgical approach in localized sRCC is unclear. Some advocate for radical nephrectomy, although observational data suggest that partial nephrectomy may not be inferior in tumors less than 7 cm (T1 disease) [31]. An extensive lymphadenectomy at the time of surgery may improve
outcomes in this high-risk population [32, 33]. Cytoreductive nephrectomy has been shown to improve survival among patients with metastatic renal cell carcinoma and is a standard of care for selected RCC patients [34]. A population-based study among patients with metastatic sRCC who underwent cytoreductive nephrectomy has shown that patients with T1 and T2 disease have a survival benefit of more than 6 months using this approach [35]. There has been a long-standing role of metastectomy among select patients with RCC who have oligometastatic disease. Patients with a disease-free interval greater than one year, younger than 60 years old, or solitary metastasis particularly in the lung may have the most benefit [36, 37]. The role of metastectomy in sRCC is less clear and has only been reported in small cases series [38].

The role of adjuvant therapy in kidney cancer has been explored after nephrectomy. Sunitinib was compared to placebo in the S-TRAC trial in RCC with locoregional disease, which resulted in minimal improvement in disease free survival with increased toxicity; however, the number of sRCC patients was not reported in this trial [39]. Adjuvant pembrolizumab has been evaluated in RCC after nephrectomy and this effort included sRCC patients (11%). The overall results showed a 2-year disease free survival of 77% in the treatment arm vs 68% in the placebo group [40].

Role for radiation therapy

Renal cell carcinoma is considered a radioresistant tumor using standard radiotherapy (RT) approaches [41, 42]. A meta-analysis evaluating post-operative radiation after nephrectomy in renal cell carcinoma has demonstrated improvement in locoregional failure. However, this did not translate to an overall survival benefit [43]. The role of RT in the non-metastatic sRCC setting has been evaluated. Using SEER data for sRCC, adjuvant radiation therapy post nephrectomy did not improve disease specific or overall survival [44].

High doses of radiation have been classically utilized in brain and spinal metastasis in the form of stereotactic radiosurgery (SRS). SRS has also been used for radioresistant tumors like renal cell carcinoma presenting with brain metastasis demonstrating a 75% response rate [42]. This hypofractionated approach with higher doses of radiation for tumors outside of the central nervous system is known as stereotactic body radiotherapy (SBRT). The use of SBRT has been evaluated in metastatic renal cell carcinoma and melanoma, both classically characterized as radioresistant tumors. An aggressive SBRT regimen of at least 45 Gy showed efficacy in achieving local control that is comparable to more radiosensitive cancer types [43]. Treatment schedule delivering up to 48 Gy in 3 to 4 fractions have been found to be effective and safe in renal cell carcinoma with little specific data on sRCC [45]. Therefore, the role of radiation therapy in either sarcomatoid or non-sarcomatoid RCC is largely limited to localized treatment of symptomatic metastatic disease particularly to the brain and bone but may be applied to soft tissue lesions as well [44, 46]. The use of high dose of radiotherapy via SRS and SBRT appears to provide the most effective tumor control [42, 43].

Systemic therapy

Sarcomatoid renal cell carcinoma presenting with advanced or metastatic disease warrants the use of systemic therapy. These treatments include chemotherpay, targeted tyrosine kinase inhibitors, and immunotherapy. Given the rarity of sRCC and its exclusion from some clinicals, there are limited data on the most effective systemic therapy approaches. Most of the treatment guidance in sRCC is based on extrapolation of subgroup analyses from larger studies among the more common variants, particularly clear cell renal cell carcinoma. The choice of systemic therapy for advanced or metastatic renal cell carcinoma is guided by prognostic risk stratification models including the Memorial Sloan Kettering Cancer Center (MSKCC) and International Metastatic Renal cell carcinoma database consortium (IMDC) approaches. These risk stratification models classify typically classify patients with sRCC as intermediate or poor risk [47, 48].

Cytotoxic chemotherapy

Before the availability of targeted therapies and given the histologic resemblance of sRCC to sarcomas, cytotoxic chemotherapy has been evaluated in sRCC with the prospect of achieving the same responses (Table 1). In one retrospective study of fourteen sRCC patients treated with chemotherapy, 3 of the 8 patients receiving doxorubicin-based chemotherapy had a response, with an overall survival of 20, 29 and 60 months among patients who responded [49]. The combination of doxorubicin with ifosfamide, which is an active chemotherapy in soft
Table 1
Chemotherapy studies in Sarcomatoid Renal Cell Carcinoma

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of study</th>
<th>Treatment</th>
<th>N</th>
<th>ORR</th>
<th>PFS/TTP</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Culine et al.</td>
<td>Retrospective</td>
<td>Doxorubicin based</td>
<td>14</td>
<td>37.5%</td>
<td>NR</td>
<td>20–60 months</td>
</tr>
<tr>
<td>Escudier et al.</td>
<td>Phase 2</td>
<td>Doxorubicin+Ifosfamide</td>
<td>23</td>
<td>0%</td>
<td>2.2 months</td>
<td>3.9 months</td>
</tr>
<tr>
<td>Nanus et al.</td>
<td>Phase 2</td>
<td>Gemcitabine+Doxorubicin</td>
<td>18 (10 sRCC)</td>
<td>40% (sRCC)</td>
<td>5.2 months</td>
<td>NR</td>
</tr>
<tr>
<td>Haas et al.</td>
<td>Phase 2</td>
<td>Gemcitabine+Doxorubicin</td>
<td>39</td>
<td>16%</td>
<td>3.5 months</td>
<td>8.8 months</td>
</tr>
</tbody>
</table>

ORR: overall response rate; PFS: progression free survival; TTP: Time to progression; OS: overall survival; NR: Not reported.

Tissue sarcoma, has been evaluated in a multicenter study of 25 sRCC patients. The findings of this study were disappointing with no objective responses and an overall survival of only 3.9 months [50]. The combination of gemcitabine and doxorubicin was also tested in two phase 2 studies [51, 52]. In the study by Nanus et al., 18 patients with RCC were treated with the combination of gemcitabine and doxorubicin. Ten patients were classified as sRCC and among these patients, only two (20%) had a complete response while another 2 patients (20%) had mixed or partial responses [51]. In the ECOG 8802 trial involving 39 sRCC patients, only six patients (16%) of patients responded to gemcitabine and doxorubicin while about 26% had stable disease. Median progression free survival and overall survival were 3.5 months and 8.8 months respectively [52].

Treatment response to cytotoxic chemotherapy has some association with the proportion of sarcomatoid component. The ECOG 8802 trial showed that patients with 75% or greater sarcomatoid features have better response rates when treated with combination of gemcitabine and doxorubicin [52]. In a study evaluating the combination of gemcitabine and sunitinib, patients with more than 10% sarcomatoid features also had better treatment response and disease stability [53]. These data suggest that cytotoxic therapy may be a useful treatment option for some sRCC patients with higher proportions of sarcomatoid features on pathology.

In summary, cytotoxic chemotherapy generally has limited response rates and survival benefit. Unfortunately, the histologic similarities of sRCC to sarcomas has not translated to high response rates with chemotherapy. Although these studies were primarily limited by small number of subjects, single or combination chemotherapy is unlikely to yield durable clinically significant responses leading to survival benefit in sRCC.

Targeted therapy (VEGF and mTOR inhibitors)

Improved understanding of the biology of renal cell carcinoma has changed the spectrum of disease management and systemic therapy options in RCC. Targeted therapy directed against the vascular endothelial growth factor (VEGF) receptor and mammalian target of rapamycin (mTOR) pathway has been utilized as standard therapy for renal cell carcinoma patients [54–56]. Therapy directed against these pathways have been used as monotherapy or in combination with chemotherapy in sRCC (Table 2). Michaelson et al studied the combination of gemcitabine and sunitinib in sRCC, producing a response rate of 26% with greater responses among those tumors comprised of more than 10% sarcomatoid features [53]. A retrospective review evaluated the combination of gemcitabine, capecitabine and bevacizumab among sarcomatoid RCC and non-sarcomatoid RCC; over half of these patients had received prior tyrosine kinase inhibitors. Patients with sRCC in this analysis had poor PFS and OS at 3.9 months and 10.4 months respectively [57]. This combination was tested in a phase 2 trial of sRCC patients by Maiti et al., which showed a PFS of 5.5 months and OS of 12 months. The majority of patients (71%) had disease progression during the trial [58]. The use of sorafenib after progression on chemotherapy with gemcitabine and doxorubicin was studied in a phase 2 clinical trial of sRCC patients and showed a low response rate at 11.1%. The median time to progression seemed longer in this study at 10.9 months [59].

Large retrospective studies evaluating the use of various targeted therapies including multikinase inhibitors, mTOR and VEGF receptors blockers in sRCC show consistent PFS between 4 to 5 months and OS of 10 to 12 months compared to smaller prospective studies [60, 61]. Temsirolimus and everolimus, inhibitors of mTOR, which is vital in the key pathways of tumorigenesis of renal cell carci-
Table 2

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of study</th>
<th>Treatment</th>
<th>N</th>
<th>ORR</th>
<th>PFS/TTP</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Golshayan et al. [60]</td>
<td>Retrospective</td>
<td>Sunitinib; Sorafenib; Bevacizumab; Sunitinib + Bevacizumab</td>
<td>43</td>
<td>19%</td>
<td>5.3 months</td>
<td>11.8 months</td>
</tr>
<tr>
<td>Staehler et al. [59]</td>
<td>Phase 2</td>
<td>Sorafenib after progression of disease post gemcitabine and doxorubicin</td>
<td>9</td>
<td>11.1%</td>
<td>10.9 months</td>
<td>NR</td>
</tr>
<tr>
<td>Jonasch et al. [57]</td>
<td>Retrospective</td>
<td>Gemcitabine + Capcitabine + Bevacizumab</td>
<td>28 (10 sRCC)</td>
<td>NR</td>
<td>3.9 months</td>
<td>9 months (sRCC)</td>
</tr>
<tr>
<td>Voss et al. [62]</td>
<td>Retrospective</td>
<td>Temsirolimus; Everolimus</td>
<td>85 (23 sRCC)</td>
<td>13% (sRCC)</td>
<td>3.5 months</td>
<td>8.2 months (sRCC)</td>
</tr>
<tr>
<td>Michaelson et al. [53]</td>
<td>Phase 2</td>
<td>Gemcitabine + Sunitinib</td>
<td>39</td>
<td>26%</td>
<td>5 months</td>
<td>10 months</td>
</tr>
<tr>
<td>Kyriakopoulus et al. [61]</td>
<td>Retrospective</td>
<td>Sunitinib; Sorafenib; Bevacizumab; Temsirolimus; Everolimus</td>
<td>2,286 (230 sRCC)</td>
<td>7% (sRCC)</td>
<td>4.5 months</td>
<td>10.4 months (sRCC)</td>
</tr>
<tr>
<td>Maiti et al. [58]</td>
<td>Phase 2</td>
<td>Gemcitabine + Capcitabine + Bevacizumab</td>
<td>34</td>
<td>20%</td>
<td>5.5 months</td>
<td>12 months</td>
</tr>
</tbody>
</table>

ORR: overall response rate; PFS: progression free survival; TTP: Time to progression; OS: overall survival; NR: Not reported.

noma, have also been evaluated in sRCC. In a study by Voss et al., patients with sRCC receiving mTOR inhibitors had a poor response rate of 13% with no complete responses and an overall survival of only 8 months [62].

Overall, the use targeted therapies alone or in combination with chemotherapy has demonstrated disappointing response rates, PFS and overall survival. There could be value using these medications sequentially as salvage therapy after progression to offer some disease stability as seen in the study of Staehler et al. [59].

**Immunotherapy**

Immunotherapy has been utilized in the management of renal cell carcinoma with interleukin-2 (IL-2) therapy approved in 1992. Interleukin-2 (IL-2) is a cytokine that modulates the immune system by promoting the expansion of cytotoxic and regulator T-cells to produce an anti-tumor effect [63]. High dose (HD) IL-2 has generated durable responses in a limited number of patients with good and poor risk metastatic renal cell carcinoma. Median overall survival was 43 months with this approach and some patients remained progression free for an extended period [64].

A study by Achkar et al., showed low response rates to HD IL-2 at 10%, although the median overall survival of 31 months among patients with sRCC appeared higher than historical controls [65]. In a retrospective study of 199 sRCC patients receiving cytokine or targeted therapy, 61% of patients who received cytokine therapy were alive at 1 year [66]. These findings highlight the potential role of HD IL-2 in the treatment of sRCC; however, the use of IL-2 has been limited by the toxicity profile and poor tolerance of this medication.

The integration of immune checkpoint inhibitors has changed the treatment landscape in the field of oncology including RCC. Cancer cells evade the immune system by activating different immune checkpoint pathways. Immune checkpoint inhibitors use monoclonal antibodies that target cytotoxic T-lymphocyte antigen 4 (CTLA-4), Program death-1 (PD-1) and Program Death-Ligand 1 (PD-L1). The effect of this monoclonal antibody inhibition is the activation and proliferation of effector T cells directed at cancer cells [67].

The CheckMate 214 trial compared the combination of ipilimumab/nivolumab to sunitinib among patients with intermediate and poor risk renal cell carcinoma. This study demonstrated excellent overall survival and response rate with the combination of ipilimumab and nivolumab compared to sunitinib [68]. A post hoc analysis among 74 patients with sRCC who received the immune checkpoint
Table 3

Post hoc analysis of Phase III trials on Immunotherapy combination for Sarcomatoid Renal Cell Carcinoma

<table>
<thead>
<tr>
<th>Study</th>
<th>Investigational therapy</th>
<th>Comparator arm</th>
<th>N (% sRCC)</th>
<th>ORR (CR)</th>
<th>12-month OS</th>
<th>PFS</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>CheckMate 214</td>
<td>Ipilimumab + Nivolumab</td>
<td>Sunitinib</td>
<td>74 (18.2%)</td>
<td>61% (19%)</td>
<td>84%</td>
<td>26.5 months</td>
<td>Not reached</td>
</tr>
<tr>
<td>KEYNOTE 426</td>
<td>Axitinib + Pembrolizumab</td>
<td>Sunitinib</td>
<td>51 (18.2%)</td>
<td>59% (12%)</td>
<td>83%</td>
<td>Not reached</td>
<td>Not reached</td>
</tr>
<tr>
<td>JAVELIN Renal 101</td>
<td>Axitinib + Avelumab</td>
<td>Sunitinib</td>
<td>47 (12.2%)</td>
<td>47% (4%)</td>
<td>83%</td>
<td>7 months</td>
<td>NR</td>
</tr>
<tr>
<td>IMmotion 151</td>
<td>Atezolizumab + Bevacizum</td>
<td>Sunitinib</td>
<td>68 (16%)</td>
<td>49% (10%)</td>
<td>Not reached</td>
<td>8.3 months</td>
<td>21.7 months</td>
</tr>
<tr>
<td>Checkmate 9ER</td>
<td>Nivolumab + Cabozantinib</td>
<td>Sunitinib</td>
<td>75 (11.5%)</td>
<td>55.9% (CR not reported)</td>
<td>NR</td>
<td>10.9 months</td>
<td>Not reached</td>
</tr>
</tbody>
</table>

ORR: Overall response rate; CR: Complete response; PFS: progression free survival; OS: overall survival; %: percentage of overall population; NR: Not reported.

The combination of immune checkpoint inhibitor combination showed an overall response rate of 61% (19% CR). Progression free survival was 26.5 months in sRCC patients receiving ipilimumab/nivolumab. Similar to the overall population, median OS was not reached in the study among sRCC patients [69].

There are several key studies that defined a role for immune checkpoint inhibitor therapy combined with anti-VEGF in the treatment of advanced sRCC. McGregor et al evaluated the use of the combination of atezolizumab and bevacizumab among patients with RCC with non-clear cell variant and RCC with more than 20% sarcomatoid features. This combination was found to be effective and safe with a response rate of 50% among patients with sRCC [70]. The combination of axitinib and pembrolizumab was evaluated in the KEYNOTE 426 study. This combination showed improved response rates, median progression free survival and median overall survival over sunitinib [71]. Rini et al reported an exploratory analysis of the KEYNOTE 426 study among intermediate, poor risk RCC and those with sarcomatoid features. The results in the total population in this study were consistent for patients with sRCC. Overall response rate was 59%. Both the median PFS and median OS were not reached among sRCC patients receiving the combination of axitinib and pembrolizumab [72]. The combination of immune checkpoint inhibitor and anti-angiogenic agents has been examined in two other large phase III studies [73, 74]. Post hoc analysis among patients with sRCC showed improved response rates over 45% and median PFS greater than 6 months [75, 76]. The CheckMate 9ER trial compared the combination of cabozantinib plus nivolumab to sunitinib. In the subset of patients with sRCC, the overall response rate was 55.9% with a median PFS of 10.9 months [77]. The CLEAR study evaluated the combination of lenvatinib and pembrolizumab in advanced RCC, which also included sRCC (11.8%). In the overall population, median PFS was significantly longer at 23.9 months with an overall response rate as high as 71% using the combination therapy. This yielded some of the highest response rates among all the TKI+immunotherapy combinations to date in RCC patients. A post-hoc analysis in the sRCC group for the CLEAR study is not yet available but the overall findings of this combination are encouraging [78]. A phase 1 study evaluating the use of the combination of ipilimumab, cabozantinib and nivolumab (ICONIC trial) in rare metastatic genitourinary malignancies included sRCC patients with at least 50% sarcomatoid features and showed an overall response rate of 62.5% in this subset [79]. Taken together, it is clear from these trials that patients with sRCC benefit from the combination of immunotherapy and anti-angiogenic therapy.

These large prospective phase III trials have shown improved outcomes in the treatment of sRCC (Table 3). The objective response rates ranged from 47% to 61%, which also resulted in improved PFS and OS [69, 72, 75–77]. The benefit among these patients could be explained by increased PD-L1 expression and higher levels of tumor infiltrating lymphocytes (TILs) in sRCC [23, 80, 81]. It is important to highlight that despite improved outcomes of immunotherapy-based treatment in sRCC, both PFS and OS are still inferior compared to non-sarcomatoid counterparts [82].

Genomic and biomarker analysis with the combination of immune checkpoint inhibitor and anti-angiogenic therapy has shown improved outcomes in tumors with high immunogenic or anti-tumor
immunity gene profile. A low angiogenic gene signature is also predictive of response to therapy. The PD-L1 positivity and tumor mutational burden markers have not consistently predicted benefit in these large trials [83–85].

OVERALL TREATMENT APPROACH

Among patients with localized and resectable disease, nephrectomy still provides the best opportunity for cure although recurrence rates are high. Lymphadenectomy at the time of nephrectomy has been advocated among patients with sarcomatoid features given that approximately 38% of sRCC patients with high-risk features demonstrate pathologic nodal involvement at the time of surgery [32, 33]. Post nephrectomy finding of sarcomatoid features greater than 25% in the primary tumor portends worse outcomes and vigilant follow up is needed for these patients [12]. The use of pembrolizumab in the adjuvant setting may be considered in sRCC patients with data supporting improved disease-free survival [40]. The potential benefit of cytoreductive nephrectomy appears to correlate with the amount of sarcomatoid component present in the tumor and may be more beneficial in patients with T1 and T2 disease [35, 86]. Radiation therapy in the form of SRS or SBRT is an option for local disease control in patients with symptomatic metastatic disease [42–44, 46].

The majority of sRCC patients will have metastatic disease requiring the use of systemic therapy (Fig. 2). Immune checkpoint inhibitor combination or immunotherapy in combination with VEGF inhibitors have shown some of the most promising response rates and survival benefit in metastatic sRCC to date [69, 72, 75–78]. Although these data are from post hoc analyses and extrapolation from larger trials, this approach offers the most compelling preferred systemic treatment for sRCC currently. The data from the CheckMate 214 study with the use of the combination of nivolumab and ipilimumab also show very notable overall survival outcomes in the intermediate and poor risk patients with a median OS of 48.1 months in the overall population. Based on available data, this combination also has compelling complete and overall response rates in patient with sRCC [69, 87]. The data on the combination of lenvatinib and pembrolizumab has generated among the highest overall response rate reported in the overall population at 71%. The response among sRCC has not been reported [80]. Selecting the appropriate combination has generally been based on the patient’s underlying medical condition, toxicity concerns, and prognostic risk.
There are generally limited response rates and overall outcomes with the use of cytotoxic chemotherapy or targeted therapy alone [49–52]. It is important to note that in select patients with a higher proportion of sarcomatoid features there may be a benefit from gemcitabine-based chemotherapy [51, 52]. Patients with a significant proportion of sarcomatoid features, a large burden of disease, and those who need rapid responses may be candidates for chemotherapy alone or in combination with targeted therapies when there is a contraindication to immune checkpoint inhibitors. In these cases, anti-VEGF TKI chemotherapy-based regimen could be considered.

High dose IL-2 has shown some utility with response rates and survival benefit possibly better than monotherapy with targeted therapy or chemotherapy for sRCC. Although the use of HD IL-2 has limited application due to poor tolerance, this is an option for treatment among patients who are physically fit. The use of targeted therapy as a monotherapy has also shown suboptimal response and survival benefit [53, 57–62]. Combination targeted therapy and cytotoxic therapy could be considered as second line treatment for sRCC.

FUTURE DIRECTIONS IN SARCOMATOID RENAL CELL CARCINOMA

The treatment approach to metastatic RCC has changed dramatically over the last 15 years, with many new treatment options. It is important to better define which patients with sarcomatoid features will benefit from specific therapeutic options, including cytotoxic chemotherapy, targeted therapy, or immunotherapy, in order to further improve outcomes.

A promising treatment in renal cell carcinoma is the use of Hypoxia inducible factor (HIF) 2 alpha inhibitors, knowing the vital role of the von Hippel-Lindau protein (pVHL) in the transcription of HIF and tumorigenesis in renal cell carcinoma. HIF-2 alpha inhibitors have been developed among VHL associated tumors including RCC [88], Belzutifan, an oral HIF-2 alpha inhibitor, has been evaluated in VHL associated RCC, and showed overall response rate of 49 % in this population with a median duration of response not yet reached with 20.2 months of follow up [89]. This therapy was approved for use in cancers associated with VHL in August of 2021. Sarcomatoid renal cell carcinoma arising from clear cell renal cell carcinoma is known to have a higher expression of HIF [90]. The use of HIF-2 alpha inhibition alone or in combination with existing therapeutic options for sRCC including immunotherapy is an exciting avenue for future research.

The use of chemoimmunotherapy with the combination of chemotherapy and checkpoint inhibitors have been used in a variety of malignancies including lung, GI, and urothelial malignancies. Given the historical responses of sRCC to gemcitabine-based chemotherapy, this could be a potential basis of chemoimmunotherapy for sRCC in future investigations.

The success of immunotherapy and VEGF inhibitor combination in this setting provides a backbone for further combination therapy in the treatment of RCC. Precision immunotherapy with the use of monoclonal antibodies, adaptive cell therapy, and therapeutic vaccines, either alone or in combination, are approaches that have the potential to advance therapy further in the near future for sRCC [81].

Improving outcomes with adjuvant therapy is important across renal cell carcinoma. Trials implementing anti-angiogenic therapy with VEGF inhibitors in the post nephrectomy setting have been disappointing [39, 91]. The KEYNOTE- 564 study has shown benefit with the use of pembrolizumab in the adjuvant setting post-nephrectomy [40]. This study has provided a basis for further adjuvant studies using immunotherapy alone or in combination. Given the worse prognosis of localized sRCC, developing effective adjuvant treatment is paramount.

Chimeric T- Cell therapy (CAR-T cell) has seen successful in various hematologic malignancies. This is a form of immunotherapy modulation to directly attack cancer cells. Studies using CAR-T cell therapy in solid tumors include renal cell carcinoma [92, 93]. Understanding the distinct molecular biology of sRCC and its response to immunotherapy, CAR- T cell therapy is a potential therapy.

While treatment options in renal cell carcinoma have evolved over the last decade, sarcomatoid renal cell carcinoma has inferior outcomes compared to non-sarcomatoid RCC. Ongoing research to improve outcomes in this population should focus on future efforts to understand the biology and discover therapeutic options improve survival among these patients. Inclusion of sRCC in clinical trials in a meaningful way, either as a subset of larger trials or in stand-alone trials, is essential to advancing our understanding.
CONCLUSION

Sarcomatoid renal carcinoma is an aggressive tumor with high morbidity and mortality. It is believed to arise from an epithelial mesenchymal transition, giving the tumor a high metastatic potential. Patients with localized and resectable tumors should undergo a radical nephrectomy which offers a potential cure of the disease. Unfortunately, recurrence rates are high even with optimal surgical management in patients with localized disease. The role of immunotherapy and other targeted therapy in the adjuvant setting is a potential area for future investigation to improve post nephrectomy survival.

Most patients with sRCC will present with metastatic disease. The use of immune checkpoint inhibitors has changed landscape of treatment of renal cell carcinoma overall. The use of combination of anti-angiogenic medications with immunotherapy has translated to clinically meaningful improvement in response rate on overall survival in RCC patients, with the strong suggestion of this benefit extending to sRCC based on the post hoc analysis of larger trials. A dedicated research effort to further characterize the unique biologic and clinical features of sRCC is critical to advance our understanding and improve outcomes through better therapy.

ACKNOWLEDGMENTS

The authors have no acknowledgments.

FUNDING

The authors report no funding.

AUTHOR CONTRIBUTIONS

NC: performed literature search, wrote and edited manuscript; CG: editing and critical revision of the manuscript; TF: oversaw, edited and critical revision of manuscript. All authors have read and approved the final manuscript for submission.

CONFLICT OF INTEREST

NC has no relevant disclosure; CG has no relevant disclosure, TF: Has received research/clinical trial funding from Novartis, Dendreon, GTX, Janssen, Medivation, Sanofi, BMS, Roche/Genentech, Exelixis, Aragon, Sotoio, Tokai, AZ/MedImmune, Lilly, Settle Genetics, La Roche-Posay, Merck, Seagen. He has provided consulting for Janssen and Seattle Genetics.

TF is an Editorial Board member of this journal, but was not involved in the peer-review process of this manuscript nor had access to any information regarding its peer-review.

REFERENCES


